Related Experiment Videos
Myeloperoxidase Mediates Postischemic Arrhythmogenic Ventricular Remodeling.
Martin Mollenhauer1, Kai Friedrichs1, Max Lange1
1From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.).
Myeloperoxidase (MPO) deficiency significantly reduces ventricular arrhythmias after myocardial ischemia by preventing electrical instability and fibrosis. MPO is a key target for preventing heart disease progression.
Area of Science:
- Cardiovascular Research
- Molecular Cardiology
- Myocardial Ischemia
Background:
- Ventricular arrhythmias are a leading cause of death in myocardial ischemia patients.
- Myeloperoxidase (MPO) accumulates in ischemic heart tissue and is linked to adverse cardiac remodeling.
Purpose of the Study:
- To investigate the role of MPO in the development of ventricular arrhythmias following myocardial ischemia.
Main Methods:
- Utilized murine models of myocardial ischemia, including MPO-deficient (Mpo-/-) and CD11b/CD18 integrin-deficient mice.
- Assessed ventricular arrhythmias using ECG telemetry and programmed stimulation.
- Analyzed electrical conduction, connexin 43 (Cx43) expression, fibrosis, and fibroblast transdifferentiation.
- Correlated plasma MPO levels with clinical outcomes in a patient cohort.
Main Results:
- MPO deficiency markedly reduced vulnerability to ventricular arrhythmias and improved electrical conduction in the peri-infarct zone.
- MPO-dependent breakdown of Cx43 and activation of matrix metalloproteinase 7 were identified.
- Reduced MPO levels correlated with decreased postischemic fibrosis and fibroblast activation.
- Elevated plasma MPO levels in patients were associated with a history of ventricular arrhythmias or sudden cardiac death.
Conclusions:
- Myeloperoxidase is a critical mediator of postischemic myocardial remodeling and ventricular arrhythmias.
- Targeting MPO presents a potential therapeutic strategy for secondary prevention after myocardial ischemia.